FEATURES

Viewpoints

Prolonged Response to Nivolumab in Metastatic Melanoma

Prolonged Response to Nivolumab in Metastatic Melanoma

Results of a phase 1 trial may raise expectations for better outcomes with lower toxicity.

Idelalisib Plus Rituximab Highly Effective for Relapsed CLL

Idelalisib Plus Rituximab Highly Effective for Relapsed CLL

Resistance to initial therapy for patients with CLL may limit treatment options; however, rituximab combined with the PI3K inhibitor idelalisib may offer a tolerable alternative therapy.

Feature Articles

The Future of Clinical Trials: 'Smaller and Smarter'

The Future of Clinical Trials: 'Smaller and Smarter'

The time has come to "raise the bar" in cancer clinical trials.

End-of-Life Palliative Chemotherapy: More Harm Than Good?

End-of-Life Palliative Chemotherapy: More Harm Than Good?

Many patients believe that palliative chemo is curative treatment, so oncologists need to have important end-of-life discussions early in the course of cancer care.

Dust Hasn't Settled on Supreme Court's Gene Patent Ruling

Dust Hasn't Settled on Supreme Court's Gene Patent Ruling

Although dire predictions about the ruling on the biotech industry and health care have not come to pass, questions remain regarding the sequence-interpreting experience of the new crop of BRCA testing labs.

Slideshows

SYLATRON® (peginterferon alfa-2b)

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: ...

XELODA®

XELODA®

This slideshow reviews drug information for XELODA® (capecitabine) for treatment of metastatic breast cancer.

Table of Contents

Slide 3: Indication, Dosage, and ...

From the Advisory Board

Expert Perspectives on Breast Cancer Awareness Month

Expert Perspectives on Breast Cancer Awareness Month

Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs